EveryONE Medicines and Mendelian Partner to Transform UK Landscape for Rare Disease Diagnosis and Personalized Treatment
EveryONE Medicines, a company focused on pioneering individualized precision therapeutics for rare and difficult-to-diagnose conditions, and Mendelian, a leader in AI-driven rare disease case-finding, today announced a strategic partnership to enable patients in the UK to have timely access to innovative treatments.
EveryONE Medicines Announces Appointment of Michelle L. Mellion, MD, as Chief Medical Officer
EveryONE Medicines, a company pioneering a scalable, global framework to design, develop, and manufacture individualized medicines for children with life-threatening neurodegenerative diseases, announced today the appointment of Michelle L. Mellion, MD, as Chief Medical Officer. In this role, Dr. Mellion will lead the development and execution of the Company’s clinical trials, the first of which is expected to be initiated in the United Kingdom (UK) later this year and will include several types of genetically driven diseases. She will also oversee the establishment of EveryONE Medicines’ network of treatment centers globally, enabling the rapid expansion of the Company’s clinical pipeline.
EveryONE Medicines Appoints Kent Rogers as Chief Executive Officer and Josh Ofman, MD, MSHS, as Chairman of the Board
EveryONE Medicines, the first biotech company solely dedicated to developing personalized genetic medicines, announced the appointment of Kent Rogers as Chief Executive Officer and Josh Ofman, MD, MSHS as Chairman of the Board.
